Select region:

Clinical trials located in

Bron

Bron city is located in France. Currently, 20 clinical trials are being conducted in this city.

Bron is a commune in the Metropolis of Lyon, eastern France, with a rich history dating back to Roman times. Notably, it hosts the esteemed École Nationale de l’Aviation Civile (ENAC), a beacon for aviation studies. The city is also home to the Fort de Bron, a historical monument reflecting France’s military past. Bron’s cultural landscape is vibrant, highlighted by the annual Bron International Short Film Festival, which showcases global cinematic talents. Additionally, the Parilly Park offers a green oasis, emphasizing the city’s commitment to natural spaces amidst urban development.

  • CT-EU-00112349

    Testing New Therapies for Glioblastoma Brain Cancer

    Howdy there, partner! This here trial is called the GBM AGILE study, and it’s aiming to find better treatments for a type of brain cancer called glioblastoma. Now, glioblastoma is a real tough customer, but this study is taking a new approach by testing multiple therapies all at once, both for newly diagnosed cases and for those where the cancer has come back.

    The main goal is to find treatments that work better and can be matched to different types of glioblastoma. The study uses a fancy method called Bayesian response adaptive randomization to assign folks to different treatment arms based on how well those treatments are performing. The most important measure they’re looking at is overall survival – how long patients live after starting treatment.

    Some of the therapies being tested include drugs like temozolomide, lomustine, regorafenib, paxalisib, VAL-083, VT1021, and troriluzole. These come in different forms like capsules, tablets, or infusions, and the dosages and schedules vary depending on the drug. The study is set up so that new promising therapies can be added in, and ones that aren’t working so well can be removed as the trial goes on.

    FranceGermany
  • To study the effectiveness of mitotane in preventing cancer recurrence in patients with adrenocortical carcinoma

    The ADIUVO trial is focused on understanding the effectiveness of a treatment called mitotane in patients who have undergone surgery for a rare type of adrenocortical cancer. This cancer has a high chance of coming back after surgery, and previous research suggests that mitotane may help reduce this risk. However, it is important to confirm these results in a study in which patients are randomly assigned to receive mitotane or no additional treatment after surgery. This is particularly important for patients whose cancer is at low or intermediate risk of coming back because doctors need to be sure that the benefits of mitotane outweigh any side effects.

    In this study, the goal is to see if mitotane can help patients live longer without their cancer coming back. Doctors will also assess patients’ overall life expectancy, quality of life and any side effects that may occur as a result of treatment. In addition, they will check whether mitotane levels in the blood influence these results and whether there are differences in results depending on certain characteristics of the cancer.

    Treatment with mitotane will be started at a lower dose and gradually increased depending on your tolerability, with adjustments possible depending on blood levels and side effects. The main goal is to compare how long patients remain cancer-free after surgery, with particular emphasis on their overall well-being and any potential side effects of treatment.

    FranceGermanyItalyNetherlandsUnited Kingdom
  • SPI-62 as new drug for patients with ACTH-dependent Cushing’s syndrome

    This is a study focused on a new treatment option, SPI-62, for people struggling with ACTH-independent Cushing’s Syndrome. The main aim is to evaluate the efficacy and safety of SPI-62 in treating the condition.

    SPI-62 is a drug that works by inhibiting a specific enzyme in the body, potentially reducing excessive cortisol levels that contribute to the disease. During this study, participants will receive SPI-62 in oral tablet form. Dosing will vary, starting at a lower dose and potentially increasing depending on patient response and study requirements.

    The study has been designed as a Phase 2 trial, meaning that the primary focus is on understanding how well SPI-62 can treat the symptoms of hypercortisolism and what its safety profile is. Participants will be in the study for an extended period of time, with scheduled visits at baseline and then at 1, 3, 6, 9 and 12 months, followed by quarterly visits. These visits are crucial to monitor health status and treatment impact.

    One of the key aspects the researchers will be looking at is the change in HbA1c levels, a marker of blood sugar control, after both 6 and 12 weeks of treatment. This will help to understand whether SPI-62 can improve diabetes or the impaired glucose tolerance that often accompanies diabetes.

    FranceRomaniaUnited Kingdom
  • Investigating efficacy and safety of new therapy in early-stage Parkinson’s disease

    This clinical trial aims to examine BIIB122, a new medication considered to potentially slow down the progression of early-stage Parkinson’s disease in patients aged between 30–80 years old. Participants will undergo treatment with either BIIB122 or a placebo equal in appearance but devoid of actual medicine. The trial’s routine includes a single daily medication intake for a timeframe between 48 and 144 weeks. To evaluate the medication’s efficacy, patients’ symptoms and their impact on everyday life will be observed using the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). In addition to this, safety assessment of BIIB122 will be a main focus of the study. The trial treats this as a double-blind study, anonymizing whether a patient takes the BIIB122 drug or a placebo.

    AustriaFranceGermanyItalyNetherlandsPolandSpainUnited Kingdom
  • Assessing imatinib inhalation therapy for pulmonary arterial hypertension

    This clinical study aims to evaluate the safety and efficacy of an inhaled treatment called imatinib (AV-101) for patients with Pulmonary Arterial Hypertension (PAH). The trial is divided into two parts: Phase 2b and Phase 3. In Phase 2b, researchers will test three doses of AV-101 to identify the optimal dose for Phase 3. They will check this by measuring the resistance of the lung vessels — less resistance means the medicine is working. In the following Phase 3, the primary outcome will be the change in the 6-minute walk distance after 24 weeks of treatment compared to a placebo. Participants must be between 18 and 75 years old, have a diagnosis of PAH, and meet specific criteria regarding their disease severity and concomitant therapy.

    AustriaBelgiumCzechiaFranceGermanyGreeceItalyNetherlandsPolandPortugalSpainSwedenUnited Kingdom
  • Testing sotatercept with regular treatment in severe pulmonary arterial hypertension patients

    This investigation seeks to assess the effect of a new drug named Sotatercept on people who are suffering from a serious lung disease called ‘Pulmonary Arterial Hypertension’ (PAH). The trial is intended for individuals with high-risk PAH who are facing significant danger of death. The main goal is to find out if incorporating Sotatercept into the standard treatment can improve outcomes and potentially enhance the chances of survival. Participants who enroll will receive either Sotatercept in addition to their current medication or a placebo alongside their regular treatment.

    BelgiumFranceGermanyItalyNetherlandsSpainUnited Kingdom
  • Testing inhaled imatinib for pulmonary arterial hypertension

    This study is about a new medicine called imatinib (AV-101) which you breathe in as a dry powder. It’s for people who have a health problem called Pulmonary Arterial Hypertension (PAH) – when blood pressure is too high in the arteries that go from the heart to the lungs. The imatinib study will go through two stages. In the first stage, the researchers will try three different amounts of the medicine to find the best one. It will be based on how much it can reduce the resistance in the blood flow in the lungs. In the second stage, they it will be seen how far patients can walk in 6 minutes after taking the medicine for 24 weeks. The study also uses scoring systems to measure how much risk or symptoms a patient has. A higher score means more risk or symptoms.

    AustriaBelgiumCzechiaFranceGermanyGreeceItalyNetherlandsPolandPortugalSpainSwedenUnited Kingdom
  • Research on new medicine for advanced or metastatic lung cancer

    This study investigates a new medicine called JDQ443’s ability to combat advanced non-small cell lung cancer. It involves two groups based on their PD-L1 levels and mutations KRAS G12C. The study has two parts (called cohorts), each involving different people. The study is carried out in stages called ‘cycles’ which last for 21 days each. During the study, assessments will be conducted to evaluate the medicine’s effectiveness, and health monitoring will be implemented. This involves measuring factors such as the duration until disease progression and the length of survival post-treatment initiation.

    AustriaBelgiumBulgariaFranceGermanyGreeceHungaryItalyNetherlandsPortugalSpainUnited Kingdom
  • Testing the safety and effectiveness of alpelisib for MCAP syndrome

    This study is testing a medication called Alpelisib in people with a rare condition called Megalencephaly-Capillary Malformation Polymicrogyria Syndrome (MCAP). The study will be split into two sections. The first is a 6-month trial where some people will be given Alpelisib and others a placebo (a harmless, inactive substance), but no one will know which group they are in. This is to precisely measure the medication’s effects. After this, all qualifying participants will receive Alpelisib for the remaining 18 months. Participants’ progress will be monitored regularly, and the effects of the medicine will be assessed primarily using a scale that measures improvement in everyday skills and quality of life. The study also examines the medicine’s impact on brain growth and function using MRI scans and other tests.

    France
  • Testing Nipocalimab’s effect on adults with Muscle Weakness

    This study is about a new drug called nipocalimab for patients with a disease called Myasthenia Gravis (MG). MG patients feel weak in their muscles, and nipocalimab potentially could help to lessen this weakness. The drug functions by attaching itself to certain components of the blood to lessen the reaction causing muscle weakness. This large-scale study will take place in multiple hospitals and is organized in different phases including initial checks (4 weeks), treatment (24 weeks) and follow-ups (up to 2 years). It will be measured how well the treatment works through daily activity scores and strength tests.

    BelgiumCzechiaDenmarkFranceGermanyItalyPolandSpainSweden
  • Pralsetinib vs regular care in treating advanced lung cancer

    This study is looking at how effective a medication called Pralsetinib is in treating a type of lung cancer called RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer. This cancer type is difficult to treat and usually spreads to other parts of the body. The medicine will be compared to the usual treatments given for this type of cancer. Doctors want to see if Pralsetinib can slow down or stop the cancer progression and how long that lasts. Any side effects experienced by patients will be carefully monitored to understand the medication’s safety.

    BelgiumFranceGermanyItalyNetherlandsNorwayPortugalSpainUnited Kingdom
  • Study on the effectiveness of Ozanimod in treating Ulcerative Colitis

    This study is focused on evaluating the effectiveness and safety of ozanimod, a medication, in children with active ulcerative colitis, a challenging gastrointestinal condition associated with intense pain. The primary objective of the study is to investigate whether ozanimod, administered orally, can provide relief from the symptoms of active ulcerative colitis in children. Additionally, the study aims to assess the safety profile of ozanimod in this pediatric population.

    BelgiumFranceGermanyPolandSpainUnited Kingdom
  • Satralizumab treatment study for encephalitis patients

    This study is checking how well a medicine called Satralizumab works for people with two specific types of brain inflammation (swelling), known as NMDAR and LGI1 encephalitis. The study aims to see how safe this medicine is, how patient body absorbs, distributes, and gets rid of it, and how it affects the patient condition. This study involves people from different places and is controlled, which means some people will get the medicine and others will get placebo without knowing which they are taking. The study will be focused if the medicine can stop the seizures for at least 6 weeks. During the study will be provided different tests to check a physical and mental health.

    AustriaCzechiaDenmarkFranceItalyNetherlandsPoland
  • Testing mavacamten for heart muscle disease

    This study aims to assess a drug called Mavacamten for a heart condition called Non-Obstructive Hypertrophic Cardiomyopathy. Patients will be randomly given either the actual drug or a placebo without anyone knowing which one they’ve received. The study will measure how safe and effective the drug is for patients with symptoms of this heart condition. The success of the drug will be determined by preventing heart-related issues such as heart attacks, strokes, heart failures, irregular heartbeats, and the need for a heart-rhythm controlling device.

    AustriaBelgiumCzechiaDenmarkFranceGermanyHungaryItalyNetherlandsNorwayPolandPortugalSpainUnited Kingdom
  • Studying rimegepant’s effectiveness on Migraine

    This study is testing a new treatment, rimegepant, for adults with migraines who cannot take traditional migraine medications, such as triptans, possibly due to reasons like having a heart condition. The research aims to evaluate the effectiveness and tolerability of rimegepant over a 12-week period. Participants will be asked to rate their headache pain on a scale ranging from 0 (no pain) to 3 (severe pain) as one of the methods to assess the treatment’s impact.

    AustriaBelgiumDenmarkFinlandFranceGermanyItalyPolandSpainSwedenUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Comparing atogepant and topiramate for migraine prevention

    In this study, a comparison is being made between two different medicines aimed at preventing migraines in adults. Migraines manifest as severe headaches on one side of the head, accompanied by symptoms such as nausea, throbbing pain, or sensitivity to light and sound. The two medicines under comparison are named atogepant and topiramate. Atogepant is currently employed for migraine prevention in individuals experiencing migraines from 0 to 14 days per month, and the study seeks to evaluate its potential broader application. Topiramate is already widely utilized for migraine prevention. Participants in this study will be divided into two groups: one group will be administered atogepant, while the other will receive topiramate for a duration of 24 weeks. Following this period, those eligible to continue will all receive atogepant for an additional 52 weeks. The study will assess their progress and monitor any potential side effects.

    AustriaBelgiumCzechiaFranceGermanyHungaryItalyPolandPortugalUnited Kingdom
  • Study on Tolebrutinib’s ability to delay disability progression in multiple sclerosis

    This is a study that involves a specific type of multiple sclerosis (MS) called primary progressive multiple sclerosis (PPMS). In this study, a drug called SAR442168, also known as Tolebrutinib, will be tested against a placebo. The main purpose of the study is to see if this drug can slow down the progression of disability in PPMS. The researchers will also look at the drug’s effect on clinical markers, brain images (MRI), thinking abilities, physical function, and quality of life. They will also consider the safety and tolerability of this drug. How long each person will take the drug can vary, but it will be somewhere between 12 and 60 months.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalRomaniaSpainSwedenUnited Kingdom
  • Testing new treatment for advanced cancers with changes in the HER2 gene

    This medical study aims to evaluate the effectiveness of a new medication, Zongertinib (BI 1810631), in individuals facing advanced cancer, particularly cases where the cancer has originated from alterations in the HER2 gene. The study comprises two main sections. In the initial phase, the focus is on individuals who have not responded to previous cancer treatments. The primary objective is to determine the highest dose of BI 1810631 that can be safely administered. Following this, the study progresses to the second part, where the emphasis shifts to testing whether the medication can reduce the size of tumors in patients with a specific type of lung cancer. Participants will continue in the study for as long as the treatment proves beneficial and manageable for them. Regular health check-ups and tumor analyses will be conducted to monitor any potential side effects resulting from the medication.

    AustriaBelgiumFranceGermanyItalyNetherlandsPortugalSpainSwedenUnited Kingdom

See more clinical trials in other cities in France:

.